Manus Pharmaceuticals

MANUS was founded in 1993 to research and develop novel biopharmaceutical medications and nutritional supplements.
Our experienced personal consulting in the area of R&D in peptide design and synthesis, structure-functional modification, cosmetic and dermatology active peptides.

Our history

Company Mission

Help to improve the quality of life through the development and production of original peptide drugs, cosmetics, and nutraceuticals. Provision of scientific information, educational, and consulting services in peptide bioregulation.

Corporate overview

Manus Pharmaceuticals (Canada) Ltd. (Manus) is a privately owned Canadian company established in 1993, focused on the research and development of novel, peptide-based biopharmaceutical medications, and nutraceutical supplements to successfully manage various immune, hematopoietic, and neurological diseases.

We have been developing a portfolio of promising novel drugs and drug candidates using our proprietary internationally patented discovery platform for exploring synthetic peptides.

Our experienced personal consulting in the areas of R&D in peptide design and synthesis, structure-functional modification, and cosmetic and active dermatology peptides.

Manus has a solid intellectual property position, with more than 50 patents issued worldwide for the compounds and scientific platform. In addition, the company holds patents in the United States, Canada, Eurasian, and the European Union countries.

Novel peptides Discovery and Development

Peptides regulate various biochemical reactions in living organisms and serve as potential prototypes for numerous drug preparations.

Learn More

First Generation of peptide pharmaceuticals

The first generation of the platform was originally developed by Dr. V. Deigin’ team in the world-renowned Soviet Academic Shemyakin and Ovchinnikov Institute in the 1985-1990th.

Learn More

Second generation of peptide products

The major disadvantage of peptide preparations, low stability at non-invasive methods of administration, limits the use of these class compounds in medical practice.

Learn More

Company Mission

Help to improve the quality of life through the development and production of original peptide drugs, cosmetics, and nutraceuticals. Provision of scientific information, educational, and consulting services in peptide bioregulation.

Manus Pharmaceuticals (Canada) Ltd. (Manus) is a privately owned Canadian company established in 1993, focused on the research and development of novel, peptide-based biopharmaceutical medications, and nutraceutical supplements to successfully manage various immune, hematopoietic, and neurological diseases.

We have been developing a portfolio of promising novel drugs and drug candidates using our proprietary internationally patented discovery platform for exploring synthetic peptides.

Our experienced personal consulting in the areas of R&D in peptide design and synthesis, structure-functional modification, and cosmetic and active dermatology peptides.

Manus has a solid intellectual property position, with more than 50 patents issued worldwide for the compounds and scientific platform. In addition, the company holds patents in the United States, Canada, Eurasian, and the European Union countries.

В. Дейгин
D12BMAIL
Previous
Next

Corporate overview

Manus is a privately owned Canadian company focused on discovering, developing, and advancing peptide drug candidates through to clinical development and developing peptide-based nutraceuticals and peptide cosmetic products. Manus has successfully introduced novel therapeutics targeting cytopenia, rheumatoid arthritis, psoriasis, and other autoimmune diseases on the market.

Manus has a portfolio of approved drugs and drug candidates at preclinical and clinical development for disease indications for unmet medical needs. In addition, Manus has an active discovery program underway identifying new peptidomimetics for targeted clinical development and the nutraceutical market.

Manus is currently focused on R&D, non-clinical and clinical development of original peptide and peptidomimetic molecules to secure approval of the Clinical Trial Application for perspective drug candidates in North America.

Facebook Instagram Linkedin